Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Natasha Penner

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Pediatric Neurology|April 24, 2018
Safety and Efficacy of Delayed-Release Dimethyl Fumarate in Pediatric Patients With Relapsing Multiple Sclerosis (FOCUS)Raed Alroughani, Rajiv Das, Natasha Penner, et al.
Neurology and Therapy|January 18, 2022
Development of a Population Pharmacokinetic Model for the Diroximel Fumarate Metabolites Monomethyl Fumarate and 2-Hydroxyethyl Succinimide Following Oral Administration of Diroximel Fumarate in Healthy Participants and Patients with Multiple SclerosisMita Kuchimanchi, Howard Bockbrader, Nancy Dolphin, et al.
BMJ Neurology Open|March 8, 2021
Comparison of neurofilament light chain results between two independent facilitiesTobias Sejbaek, Jason P Mendoza, Natasha Penner, et al.
Advances in Therapy|September 21, 2019
Improving the Gastrointestinal Tolerability of Fumaric Acid Esters: Early Findings on Gastrointestinal Events with Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis from the Phase 3, Open-Label EVOLVE-MS-1 StudyMichael J Palte, Angela Wehr, Mark Tawa, et al.
CPT: Pharmacometrics & Systems Pharmacology|January 16, 2026
Brain Amyloid Plaque Levels Affect Clinical Progression in Alzheimer Disease: Assessment of Amyloid PET and Change in CDR-SB Utilizing Semi-Mechanistic ModelPratik Bhagunde, Natasha Penner, Brian A Willis, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Drug DevelopmentLarisa Reyderman, Natasha Penner, Pratik Bhagunde, et al.
Alzheimer'S & Dementia (New York, N. Y.)|April 23, 2026
Pharmacokinetic/pharmacodynamic analyses of plasma pathophysiology biomarkers in subjects with early Alzheimer's disease following lecanemab treatmentPratik Bhagunde, Natasha Penner, Brian A Willis, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Drug DevelopmentSteven Hersch, Michelle Gee, Thomas Doherty, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
Drug DevelopmentNatasha Penner, Sumit Rawal, Jagadeesh Aluri, et al.
NPJ Systems Biology and Applications|March 6, 2026
Neuro-Dynamic Quantitative Systems Pharmacology (QSP) model describing Alzheimer's disease pathophysiology and treatment effectsYoufang Cao, Brian A Willis, Kanta Horie, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Pediatric Neurology|April 24, 2018
Safety and Efficacy of Delayed-Release Dimethyl Fumarate in Pediatric Patients With Relapsing Multiple Sclerosis (FOCUS)Raed Alroughani, Rajiv Das, Natasha Penner, et al.
Neurology and Therapy|January 18, 2022
Development of a Population Pharmacokinetic Model for the Diroximel Fumarate Metabolites Monomethyl Fumarate and 2-Hydroxyethyl Succinimide Following Oral Administration of Diroximel Fumarate in Healthy Participants and Patients with Multiple SclerosisMita Kuchimanchi, Howard Bockbrader, Nancy Dolphin, et al.
BMJ Neurology Open|March 8, 2021
Comparison of neurofilament light chain results between two independent facilitiesTobias Sejbaek, Jason P Mendoza, Natasha Penner, et al.
Advances in Therapy|September 21, 2019
Improving the Gastrointestinal Tolerability of Fumaric Acid Esters: Early Findings on Gastrointestinal Events with Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis from the Phase 3, Open-Label EVOLVE-MS-1 StudyMichael J Palte, Angela Wehr, Mark Tawa, et al.
CPT: Pharmacometrics & Systems Pharmacology|January 16, 2026
Brain Amyloid Plaque Levels Affect Clinical Progression in Alzheimer Disease: Assessment of Amyloid PET and Change in CDR-SB Utilizing Semi-Mechanistic ModelPratik Bhagunde, Natasha Penner, Brian A Willis, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Drug DevelopmentLarisa Reyderman, Natasha Penner, Pratik Bhagunde, et al.
Alzheimer'S & Dementia (New York, N. Y.)|April 23, 2026
Pharmacokinetic/pharmacodynamic analyses of plasma pathophysiology biomarkers in subjects with early Alzheimer's disease following lecanemab treatmentPratik Bhagunde, Natasha Penner, Brian A Willis, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Drug DevelopmentSteven Hersch, Michelle Gee, Thomas Doherty, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
Drug DevelopmentNatasha Penner, Sumit Rawal, Jagadeesh Aluri, et al.
NPJ Systems Biology and Applications|March 6, 2026
Neuro-Dynamic Quantitative Systems Pharmacology (QSP) model describing Alzheimer's disease pathophysiology and treatment effectsYoufang Cao, Brian A Willis, Kanta Horie, et al.
Pageof 2